MTS Health Partners

Zymeworks Inc. is a clinical-stage biopharmaceutical company based in Vancouver, Canada, focused on the discovery, development, and commercialization of innovative biotherapeutics for cancer treatment. The company's lead candidates include ZW25, a bispecific antibody undergoing Phase I and II clinical trials for various tumors, including biliary tract and gastroesophageal adenocarcinomas, and ZW49, a bispecific antibody-drug conjugate in Phase I trials for advanced HER2-expressing cancers. Zymeworks employs a computational biotechnology approach, utilizing proprietary molecular modeling and simulation technologies to optimize therapeutic antibodies and other protein-based therapeutics. The company has established strategic partnerships with notable organizations such as Merck, Eli Lilly, and Bristol-Myers Squibb, as well as collaborations aimed at advancing antibody discovery and development. Founded in 2003, Zymeworks is dedicated to addressing unmet medical needs through its advanced therapeutic platforms and integrated drug development capabilities.

myNEXUS, Inc. is a healthcare management company that specializes in technology-driven care management services, focusing on enabling individuals to manage their health effectively at home. The company provides daily remote monitoring of patients' health, particularly targeting those with chronic conditions such as congestive heart failure, diabetes, and hypertension. Through its myLINK2Care system, myNEXUS ensures immediate responses to health issues, thereby reducing the likelihood of unnecessary healthcare visits and costly hospitalizations. The company also offers benefits management services that utilize medical data to decrease the risk of 30-day readmissions. myNEXUS serves a diverse clientele, including insurers, employers, and family members, addressing the healthcare needs of individuals across the United States. Founded in 2014, the company is headquartered in Brentwood, Tennessee.